SK Biopharmaceuticals Co., Ltd.
KSC: 326030.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dong Hoon Lee
- Employees
- 241
- Headquarters
- Seongnam-si, South Korea
- IPO year
- 2020
- Market cap
- ₩7.8T
- Website
- https://www.skbp.com
Loading 326030…
Loading profile data…Frequently asked questions about 326030
What does SK Biopharmaceuticals Co., Ltd. (326030.KS) do?
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal...
Where does 326030.KS trade?
SK Biopharmaceuticals Co., Ltd. (326030.KS) trades on the Korea Exchange.
What sector is 326030.KS in?
SK Biopharmaceuticals Co., Ltd. (326030.KS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SK Biopharmaceuticals Co., Ltd.?
Dong Hoon Lee is the chief executive officer of SK Biopharmaceuticals Co., Ltd. (326030.KS).
Where is SK Biopharmaceuticals Co., Ltd. headquartered?
SK Biopharmaceuticals Co., Ltd. is headquartered in South Korea.
Does 326030.KS pay a dividend?
SK Biopharmaceuticals Co., Ltd. (326030.KS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 326030.KS go public?
SK Biopharmaceuticals Co., Ltd. (326030.KS) completed its initial public offering in 2020.